A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy

被引:4
|
作者
Osei, Ernest [1 ,2 ,3 ,4 ]
Lumini, Julia [5 ]
Gunasekara, Dinindu [2 ]
Osei, Beverley [6 ]
Asare, Akua [7 ]
Laflamme, Raymond [8 ]
机构
[1] Grand River Reg Canc Ctr, Dept Med Phys, Kitchener, ON, Canada
[2] Univ Waterloo, Dept Phys & Astron, Waterloo, ON, Canada
[3] Univ Waterloo, Dept Syst Design Engn, Waterloo, ON, Canada
[4] Univ Guelph, Dept Clin Studies, Ontario Vet Coll, Guelph, ON, Canada
[5] Univ Waterloo, Dept Biol, Waterloo, ON, Canada
[6] McMaster Univ, Dept Hlth Sci, Hamilton, ON, Canada
[7] Brock Univ, Dept Gen Sci, St Catharines, ON, Canada
[8] Univ Waterloo, Inst Quantum Comp, Waterloo, ON, Canada
关键词
cancer therapy; chromosome aberration; genes biomarkers; non-small-cell lung cancer; protein biomarkers; CLINICALLY SELECTED PATIENTS; ANAPLASTIC LYMPHOMA KINASE; PI3K PATHWAY; OPEN-LABEL; RESISTANCE MUTATION; ACQUIRED-RESISTANCE; GEFITINIB TREATMENT; MEK INHIBITORS; EARLY-STAGE; PHASE-III;
D O I
10.1017/S1460396919000876
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Lung cancer has a high mortality rate mainly due to the lack of early detection or outward signs and symptoms, thereby often progressing to advanced stages (e.g., stage IV) before it is diagnosed. However, if lung cancers can be diagnosed at an early stage and also if clinicians can prospectively identify patients likely to respond to specific treatments, then there is a very high potential to increase patients' survival. In recent years, several investigations have been conducted to identify cancer biomarkers for lung cancer risk assessment, early detection and diagnosis, the likelihood of identifying the group of patients who will benefit from a particular treatment and monitoring patient response to treatment. Materials and Methods: This paper reports on the review of 19 current clinical and emerging biomarkers used in risk assessment, screening for early detection and diagnosis and monitoring the response of treatment of non-small-cell lung cancers. Conclusion: The future holds promise for personalised and targeted medicine from prevention, diagnosis to treatment, which take into account individual patient's variability, though it depends on the development of effective biomarkers interrogating the key aberrant pathways and potentially targetable with molecular targeted or immunologic therapies. Lung cancer biomarkers have the potential to guide clinical decision-making since they can potentially detect the disease early, measure the risk of developing the disease and the risk of progression, provide accurate information of patient response to a specific treatment and are capable of informing clinicians about the likely outcome of a cancer diagnosis independent of the treatment received. Moreover, lung cancer biomarkers are increasingly linked to specific molecular pathway deregulations and/or cancer pathogenesis and can be used to justify the application of certain therapeutic or interventional strategies.
引用
收藏
页码:370 / 384
页数:15
相关论文
共 50 条
  • [21] Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review
    Cortinovis, Diego
    Malapelle, Umberto
    Pagni, Fabio
    Russo, Alessandro
    Banna, Giuseppe Luigi
    Sala, Elisa
    Rolfo, Christian
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) : 3385 - 3400
  • [22] Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer
    Passaro, A.
    Palazzo, A.
    Trenta, P.
    Mancini, M. L.
    Morano, F.
    Cortesi, E.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (22) : 3689 - 3700
  • [23] Review of the current targeted therapies for non-small-cell lung cancer
    Nguyen, Kim-Son H.
    Neal, Joel W.
    Wakelee, Heather
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 576 - 587
  • [24] Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer
    Liu, Qingyun
    Yu, Zubin
    Yuan, Shuai
    Xie, Weijia
    Li, Chengying
    Hu, Zeyao
    Xiang, Ying
    Wu, Na
    Wu, Long
    Bai, Li
    Li, Yafei
    ONCOTARGET, 2017, 8 (08) : 13048 - 13058
  • [25] EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
    Fang, Shu
    Wang, Zhehai
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 1595 - 1611
  • [26] Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer
    Tartarone, Alfredo
    Lerose, Rose
    Gallucci, Giuseppina
    Ardito, Raffaele
    Aieta, Michele
    MEDICAL ONCOLOGY, 2012, 29 (03) : 1599 - 1605
  • [27] Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer
    Alfredo Tartarone
    Rose Lerose
    Giuseppina Gallucci
    Raffaele Ardito
    Michele Aieta
    Medical Oncology, 2012, 29 : 1599 - 1605
  • [28] Prognostic and Predictive Value of Cell Cycle Deregulation in Non-Small-Cell Lung Cancer
    Sterlacci, William
    Fiegl, Michael
    Tzankov, Alexandar
    PATHOBIOLOGY, 2012, 79 (04) : 175 - 194
  • [29] Personalised treatment of non-small-cell lung cancer patients - review of current evidence
    Zysk, Rafal
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 23 - 34
  • [30] A review of current clinical biomarkers for prostate cancer: towards personalised and targeted therapy
    Osei, Ernest
    Swanson, Steph
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2022, 21 (02) : 277 - 286